

**Wright Medical Group N.V.**  
**Supplemental Net Sales Information**  
(unaudited)

**Three months ended December 30, 2018 net sales growth/(decline)**

<b>Product line</b>	<b><u>U.S. as reported</u></b>	<b><u>Int'l constant currency</u></b>	<b><u>Int'l as reported</u></b>	<b><u>Global constant currency</u></b>	<b><u>Global as reported</u></b>
Lower extremities	15%	4%	1%	13%	12%
Upper extremities	9%	11%	7%	10%	8%
Biologics	10%	11%	9%	10%	10%
Sports med & other	15%	(27%)	(29%)	(12%)	(13%)
<b>Total net sales</b>	12%	6%	3%	10%	9%

**Fiscal year ended December 30, 2018 net sales growth/(decline)**

<b>Product line</b>	<b><u>U.S. as reported</u></b>	<b><u>Int'l constant currency</u></b>	<b><u>Int'l as reported</u></b>	<b><u>Global constant currency</u></b>	<b><u>Global as reported</u></b>
Lower extremities	10%	2%	4%	8%	9%
Upper extremities	17%	18%	21%	17%	18%
Biologics	6%	16%	16%	8%	8%
Sports med & other	3%	(25%)	(22%)	(15%)	(13%)
<b>Total net sales</b>	12%	9%	12%	12%	12%

**Wright Medical Group N.V.**

**Reconciliation of Adjusted Non-GAAP Earnings Per Share to Net (Loss) Income from Continuing Operations Per Share**

(dollars in thousands, except per share data--unaudited)

	Three months ended		Fiscal year ended	
	December 30, 2018	December 31, 2017	December 30, 2018	December 31, 2017
<b>Net (loss) income from continuing operations, as reported</b>	\$ (22,947)	\$ 26,852	\$ (169,304)	\$ (64,937)
Weighted-average diluted shares outstanding	125,323	106,578	112,592	104,531
<b>Net (loss) income from continuing operations per share, as reported</b>	(0.18)	0.25	(1.50)	(0.62)
Reconciling items:				
Inventory step-up amortization	352	—	352	—
Non-cash interest expense on convertible notes <sup>1</sup>	12,573	11,746	49,186	45,489
Non-cash loss on extinguishment of debt <sup>2</sup>	—	—	39,935	—
Derivatives mark-to-market adjustments <sup>2</sup>	1,591	(634)	35,934	(4,797)
Transaction and transition costs	7,826	2,915	12,013	12,400
Incentive and indirect tax projects <sup>3</sup>	—	(9,774)	—	(9,774)
Foreign currency translation expense <sup>2</sup>	338	—	3,232	—
CVR mark-to-market adjustments <sup>2</sup>	3,224	(1,401)	140	5,320
Contingent consideration fair value adjustment <sup>2</sup>	683	(228)	1,789	81
Tax provision due to a change in judgment regarding our ability to realize certain deferred tax assets <sup>4</sup>	2,675	—	2,675	—
Tax benefit related to realizability of deferred tax assets as a result of the Cartiva acquisition <sup>4</sup>	(3,614)	—	(3,614)	—
Tax law reform <sup>4</sup>	—	(8,255)	—	(8,255)
Tax benefit related to realizability of net operating losses <sup>4</sup>	—	(16,037)	—	(24,965)
U.S. tax provision (benefit) resulting from income from discontinued operations <sup>4</sup>	3,774	—	(193)	—
Tax effect of reconciling items <sup>5</sup>	277	(1,728)	1,242	(1,798)
<b>Non-GAAP net income (loss) from continuing operations, as adjusted</b>	\$ 6,752	\$ 3,456	\$ (26,613)	\$ (51,236)
Add back amortization of intangible assets	7,699	6,822	26,730	28,396
<b>Adjusted non-GAAP earnings</b>	<b>\$ 14,451</b>	<b>\$ 10,278</b>	<b>\$ 117</b>	<b>\$ (22,840)</b>
Adjusted non-GAAP weighted-average diluted shares outstanding <sup>6</sup>	127,202	106,578	113,959	104,531
<b>Adjusted non-GAAP earnings per share</b>	<b>\$ 0.11</b>	<b>\$ 0.10</b>	<b>\$ 0.00</b>	<b>\$ (0.22)</b>

<sup>1</sup> Impacting interest expense, net.

<sup>2</sup> Impacting other expense (income), net.

<sup>3</sup> Incentive and indirect tax projects include \$0.6 million of other income and \$0.2 million of interest income.

<sup>4</sup> Impacting provision (benefit) from income taxes.

<sup>5</sup> Determined based upon the effective tax rate in the jurisdiction in which the expense was incurred.

<sup>6</sup> Adjusted non-GAAP weighted-average diluted shares outstanding includes common stock equivalents of 1.9 million and 1.4 million for the three and twelve months ended December 30, 2018, based on the income position of our adjusted non-GAAP earnings.

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted EBITDA to Net (Loss) Income from Continuing Operations**  
(dollars in thousands--unaudited)

	Three months ended		Fiscal year ended	
	December 30, 2018	December 31, 2017	December 30, 2018	December 31, 2017
<b>Net (loss) income from continuing operations</b>	\$ (22,947)	\$ 26,852	\$ (169,304)	\$ (64,937)
Interest expense, net	20,004	19,132	80,247	74,644
Provision (benefit) for income taxes	681	(27,470)	(536)	(34,968)
Depreciation	16,511	14,708	59,497	56,832
Amortization	7,699	6,822	26,730	28,396
<b>Non-GAAP EBITDA</b>	<b>\$ 21,948</b>	<b>\$ 40,044</b>	<b>\$ (3,366)</b>	<b>\$ 59,967</b>
Reconciling items impacting EBITDA:				
Non-cash share-based compensation expense	7,784	5,262	26,120	19,393
Other expense (income), net	6,148	(1,305)	81,797	5,570
Inventory step-up amortization	352	—	352	—
Transaction and transition costs	7,826	2,915	12,013	12,400
Incentive and indirect tax projects	—	(8,965)	—	(8,965)
<b>Non-GAAP adjusted EBITDA</b>	<b>\$ 44,058</b>	<b>\$ 37,951</b>	<b>\$ 116,916</b>	<b>\$ 88,365</b>
Net sales from continuing operations	238,147	217,602	836,190	744,989
<b>Non-GAAP adjusted EBITDA margin</b>	<b>18.5%</b>	<b>17.4%</b>	<b>14.0%</b>	<b>11.9%</b>

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Margins from Continuing Operations**  
(dollars in thousands--unaudited)

	Three months ended		Fiscal year ended	
	December 30, 2018	December 31, 2017	December 30, 2018	December 31, 2017
<b>Gross profit from continuing operations, as reported</b>	\$ 188,998	\$ 170,324	\$ 656,037	\$ 584,042
<b>Gross margins from continuing operations, as reported</b>	<b>79.4 %</b>	<b>78.3 %</b>	<b>78.5 %</b>	<b>78.4 %</b>
Reconciling items impacting gross profit:				
Inventory step-up amortization	352	—	352	—
Transaction and transition costs	801	1,100	4,421	3,095
<b>Non-GAAP gross profit from continuing operations, as adjusted</b>	<b>\$ 190,151</b>	<b>\$ 171,424</b>	<b>\$ 660,810</b>	<b>\$ 587,137</b>
Net sales from continuing operations	238,147	217,602	836,190	744,989
<b>Non-GAAP adjusted gross margins from continuing operations</b>	<b>79.8%</b>	<b>78.8%</b>	<b>79.0%</b>	<b>78.8%</b>

**Wright Medical Group N.V.**  
**Reconciliation of Other Non-GAAP Financial Measures to Other As Reported Results**  
(dollars in thousands--unaudited)

	Three months ended		Fiscal year ended	
	December 30, 2018	December 31, 2017	December 30, 2018	December 31, 2017
<b>Net sales</b>	\$ 238,147	\$ 217,602	\$ 836,190	\$ 744,989
<b>Selling, general and administrative expense, as reported</b>	\$ 160,664	\$ 133,149	\$ 577,961	\$ 525,222
Selling, general and administrative expense as a percentages of net sales, as reported	67.5 %	61.2 %	69.1 %	70.5 %
Reconciling items impacting selling, general and administrative expense:				
Transaction and transition costs - selling, general and administrative	7,025	1,746	7,592	9,014
Incentive and indirect tax projects	—	(8,965)	—	(8,965)
<b>Selling, general and administrative expense, as adjusted</b>	<b>\$ 153,639</b>	<b>\$ 140,368</b>	<b>\$ 570,369</b>	<b>\$ 525,173</b>
<b>Selling, general and administrative expense as a percentage of net sales, as adjusted</b>	<b>64.5%</b>	<b>64.5%</b>	<b>68.2%</b>	<b>70.5%</b>
<b>Research &amp; development expense, as reported</b>	\$ 16,749	\$ 13,144	\$ 59,142	\$ 50,115
Research & development expense as a percentages of net sales, as reported	7.0 %	6.0 %	7.1 %	6.7 %
Reconciling items impacting research & development expense:				
Transaction and transition costs - research & development	—	69	—	291
<b>Research &amp; development expense, as adjusted</b>	<b>\$ 16,749</b>	<b>\$ 13,075</b>	<b>\$ 59,142</b>	<b>\$ 49,824</b>
<b>Research &amp; development expense as a percentage of net sales, as adjusted</b>	<b>7.0%</b>	<b>6.0%</b>	<b>7.1%</b>	<b>6.7%</b>